We dont know the long-term effects these drugs have on children who take them
Based on Phase 2 safety data (Jastreboff et al., NEJM 2023), common early adverse effects reported include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea or constipation Reduced appetite Mild fatigue or dizziness These effects are consistent with the GLP-1 receptor agonist class and typically reflect the gut's adaptation to altered gastric emptying and hormonal signalling
Eligibility for Ongoing Maintenance Treatment Before approving ongoing maintenance treatment or restarting medication following a treatment break, our clinicians will complete the necessary clinical and safety assessments to confirm that treatment remains safe, clinically appropriate, and suitable for you
Other Factors That May Affect Urination During GLP-1 Therapy Several concurrent factors may influence urinary patterns in patients taking GLP-1 medications, and it is important to consider these when evaluating symptoms: Concomitant medications : Many patients on GLP-1 therapy take other medications that affect urination
Ca2+ dyshomeostasis links risk factors to neurodegeneration in Parkinsons disease
It typically resolves within 2 to 3 weeks of continued use
